Categories Earnings, Health Care

Earnings Summary: Highlights of Organon’s Q2 2023 results

Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023.

  • Second-quarter revenue came in at $1.61 billion, which is up 1% year-over-year
  • Earnings per share increased to $0.95 in the June quarter from $0.92 last year
  • Adjusted earnings were $1.31 per share in Q2, compared to $1.25 per share in the second quarter of 2022
  • The company reported second-quarter adjusted EBITDA of $530 million, which is up 4% annually
  • The management expects full-year 2023 revenue to be in the range of $6.25 billion to $6.45 billion
  • Adjusted EBITDA margin for 2023 is currently expected to be between 31.5% and 33.0%

Most Popular

WBA Earnings Preview: Will Walgreens’ Q3 report bring cheer to investors?

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has been facing challenges due to higher operating costs, rising competition, and an unfavorable retail environment. These factors have put pressure on the drugstore

Main points from Accenture’s (ACN) Q3 2024 earnings report

Shares of Accenture (NYSE: ACN) rose 6% on Thursday, following the company’s announcement of its third-quarter 2024 earnings results. Although revenue and profits missed expectations, the stock jumped after the

ACB Earnings: Aurora Cannabis reports narrower Q4 loss on higher revenues

Aurora Cannabis, Inc. (NASDAQ: ACB) on Thursday reported a net loss for the fourth quarter of 2024. The company’s revenues moved up 5% year-over-year during the quarter. The Canada-based recreational

Add Comment
Viewing Highlight